Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
Crinetics Pharmaceuticals reported over $5 million in preliminary net product revenue for PALSONIFY in Q4 2025, while Phase 2 data for its congenital adrenal hyperplasia treatment showed promising results that analysts say have derisked the Phase 3 study design.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07159841 |
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) |
RECRUITING | PHASE2/PHASE3 |
| NCT07144163 |
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia |
RECRUITING | PHASE3 |
